Detalhe da pesquisa
1.
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Pediatr Blood Cancer
; 61(4): 636-42, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24123865